An Open-Label, Single-Dose, Parallel-Group Study Of The Pharmacokinetics And Safety Of Bosutinib In Subjects With Renal Impairment And Matched Healthy Adults

Trial Profile

An Open-Label, Single-Dose, Parallel-Group Study Of The Pharmacokinetics And Safety Of Bosutinib In Subjects With Renal Impairment And Matched Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2014

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Autosomal dominant polycystic kidney disease; Chronic myeloid leukaemia
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top